HOME >> MEDICINE >> NEWS
First trimester use of ACE inhibitors implicated in birth defects

The Food and Drug Administration is examining study data from Vanderbilt University Medical Center researchers, published this week in the New England Journal of Medicine, to determine if new warnings should be placed on common blood pressure medications indicating an increased risk of birth defects for babies whose mothers take these medications during the first trimester of pregnancy.

The study, led by William Cooper, M.D., M.P.H., associate professor of Pediatrics at the Monroe Carell Jr. Children's Hospital at Vanderbilt, found infants born to mothers who took angiotensin converting enzyme inhibitors (ACE inhibitors) during the first trimester of pregnancy had an increased risk of major birth defects, compared with infants whose mothers did not take these medications.

Out of 29,507 infants whose TennCare records were examined for the study, 209 were exposed to ACE inhibitors in the first trimester only. When those babies were compared to the rest of the population, including babies exposed to other types of antihypertensive medications, they had more than double the risk of major birth defects, especially of the heart and central nervous system.

Cooper is first author on the study, which includes co-authors from the Departments of Pediatrics, Preventive Medicine and Biostatistics.

"We knew ACE inhibitors were a possible cause of adverse fetal outcomes when exposure occurred later in pregnancy, but it has not been well studied in the first trimester," Cooper said. "We were very surprised that even after controlling for other risk factors, the TennCare records we examined showed a clear increase in a broad range of birth defects following first-trimester-only exposures."

This research is important because of an increase in the number of women of childbearing age who develop high blood pressure and are prescribed ACE inhibitors. These drugs already carry a warning that they may cause injury and even death to t
'"/>

Contact: Carole Bartoo
carole.bartoo@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
7-Jun-2006


Page: 1 2

Related medicine news :

1. First of its kind report on how children with brain tumors perform at school
2. First clinical trial of gene therapy for childhood blindness
3. First nationwide child health and air pollution study commences
4. First step in developing heart hormone-based pill to control high blood pressure
5. First greenhouse gas animations produced using Envisat SCIAMACHY data
6. First ozone and nitrogen dioxide measurements from MetOp-A
7. First-degree fetal heart block may be reversible
8. 10 outstanding scientists chosen as First Environmental Health Science Fellows
9. First-time mothers at increased risk for postpartum mental disorders
10. Transforming knowledge into economic benefits -- EPSRCs First Knowledge Transfer Challenge Awards
11. First Quantum Grant to fund stem cell repair of damage from stroke

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: First trimester use ACE inhibitors implicated birth defects

(Date:8/31/2015)... ... August 31, 2015 , ... It’s a lot like coming home. Life-long ... of Geneva. During his first days on the job, he’s run into residents of ... and I like knowing that they’re living in such a wonderful place,” he said. ...
(Date:8/31/2015)... Riviera Beach, FL (PRWEB) , ... August 31, 2015 , ... ... Wilander to their growing list of major sports figures who are finding joint pain ... Slam titles, and former #1 men’s tennis player in the world said, “For the ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... the Talent Management Division , a department devoted to helping organizations identify ... Talent management goes beyond selection, and The Brooks Group believes in offering a ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... networking and relationship-marketing firm, announced today the nominees vying for the 2015 ... U.S. Region. Executives include top-ranking decision makers representing national to global organizations ...
(Date:8/31/2015)... ... August 31, 2015 , ... PartnerTech hosted ... Owners and provided a tour of their North American facility following the S.M.A.R.T ... international companies expanding business in the U.S. , The PartnerTech Inc. North ...
Breaking Medicine News(10 mins):Health News:Friendship Senior Options Welcomes New Executive Director for GreenFields of Geneva 2Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 2Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 3Health News:The Brooks Group Introduces Talent Management Division 2Health News:The Brooks Group Introduces Talent Management Division 3Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 2Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 3Health News:T.E.N. Announces Nominees for the 2015 ISE® Northeast Awards; People's Choice voting now open 4Health News:PartnerTech Supports Economic Growth as Host 2
(Date:8/31/2015)... , Aug. 31, 2015  QT Vascular Ltd., together ... and together with its subsidiaries, the "Group"), a ... distribution of advanced therapeutic solutions for the minimally ... final results of the below-the-knee ("BTK") cohort of ... which were presented on August 15, 2015 at ...
(Date:8/31/2015)... Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical company ... for the treatment of diseases of the central nervous ... IND submission has passed review by the US Food ... Phase 1 clinical trial in patients with metastatic colon ... to 31 December 2015. Bionomics, CEO & ...
(Date:8/31/2015)... 2015   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... media and a related cloud hosted ... smart shippers ("BioLife" or the "Company"), today ... biopharmaceutical company focused on developing and commercializing novel ...
Breaking Medicine Technology:Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 2Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 3Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 4Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5
Cached News: